EUVIMEDEUVIMED entdecken
Open Access

Cost-Effectiveness of Anticoagulation Treatment for Subclinical Device-Detected Atrial Fibrillation

Aleksi K Winstén, Ville Langén, K E Juhani Airaksinen, Konsta Teppo

JAMA Network Open · 2026

DOI: 10.1001/jamanetworkopen.2026.17213 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2026. Verfasst von Aleksi K Winstén und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mathematics and Statistics, University of Turku, Turku, Finland. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anticoagulants, Stroke. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Anticoagulation for stroke prevention in subclinical, device-detected atrial fibrillation (AF) remains an area of clinical equipoise, and its cost-effectiveness is unknown.

Objective

To evaluate the cost-effectiveness of direct oral anticoagulant (DOAC) therapy in patients with device-detected AF. Design, Setting, and Participants This economic evaluation was a cost-effectiveness analysis using a Markov model comparing initiation of DOAC therapy vs no anticoagulation over a 10-year time horizon. Base-case analyses modeled 10 000 patients per strategy with device-detected subclinical AF, with baseline characteristics and risks of stroke, bleeding, and mortality reflecting those observed in randomized clinical trials. The evaluation was conducted from the health system perspective, with treatment and event costs derived from Nordic health care data. The modeling was conducted on March 10, 2026. Exposure The associations of DOAC therapy with the risk and severity of clinical events were incorporated into the analysis, based on a meta-analysis of trials evaluating DOAC therapy in subclinical AF. Probabilistic sensitivity analysis also considered the 95% CIs in the reported treatment effect sizes. Main Outcomes and Measures Incremental quality-adjusted life-years (QALYs), costs, and the incremental cost-effectiveness ratio (ICER; cost difference per QALY gained) from a health system perspective, with 3% annual discounting of both costs and QALYs. Cost-effectiveness was assessed using a €50 000 per QALY willingness-to-pay threshold.

Results

The mean age of the 20 000-person simulated cohort was 77 years. In the base case analysis, DOAC therapy was associated with an additional 0.016 QALYs and an incremental cost of €1676 per patient, resulting in an ICER of €105 293 per QALY. In probabilistic sensitivity analysis, DOAC therapy was cost-effective in 35% of simulations and dominated in 38%, with a mean QALY gain of 0.016 per patient, a mean incremental cost of €2883 per patient, and a mean ICER of €176 772. Probabilistic sensitivity analyses by CHA 2 DS 2 -VASc (congestive heart failure; hypertension; age ≥75 years; diabetes; prior stroke, transient ischemic attack, or thromboembolism; vascular disease; age 65-74 years; and sex category) score showed probabilities of cost-effectiveness of 31%, 41%, and 52% for patients with scores less than 4, of 4, and greater than 4, respectively. Conclusions and Relevance This economic evaluation found that routinely initiating DOAC therapy in all patients with device-detected subclinical AF is unlikely to be cost-effective. Whether treatment is cost-effective in patients with very high CHA 2 DS 2 -VASc scores is uncertain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationAnticoagulantsStrokeHumansCost-Benefit AnalysisCost-Effectiveness AnalysisFemaleQuality-Adjusted Life YearsMaleAgedMarkov Chains

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Mathematics and Statistics, University of Turku, Turku, Finland.
  • Faculty of Medicine, University of Turku, Turku, Finland.
  • Division of Medicine, Turku University Hospital and University of Turku, Turku, Finland.
  • Turku University Hospital and University of Turku, Turku, Finland.
  • Cardiac Unit, Department of Internal Medicine, Satasairaala, Pori, Finland.
  • Department of Internal Medicine, University of Turku, Turku, Finland.

Zitieren

APA

Winstén, A. K., Langén, V., Airaksinen, K. E. J., & Teppo, K. (2026). Cost-Effectiveness of Anticoagulation Treatment for Subclinical Device-Detected Atrial Fibrillation. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.17213

Vancouver

Winstén AK, Langén V, Airaksinen KEJ, Teppo K. Cost-Effectiveness of Anticoagulation Treatment for Subclinical Device-Detected Atrial Fibrillation. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.17213

BibTeX
@article{Winstn2026,
  author = {Winstén, Aleksi K and Langén, Ville and Airaksinen, K E Juhani and Teppo, Konsta},
  title = {Cost-Effectiveness of Anticoagulation Treatment for Subclinical Device-Detected Atrial Fibrillation},
  journal = {JAMA Network Open},
  year = {2026},
  doi = {10.1001/jamanetworkopen.2026.17213}
}
Kostenlos starten →